NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc. (NASDAQ: TLRY), a global pioneer in cannabis production and distribution, today announced that it has successfully exported medical cannabis from Canada to Australia to distribute to critically ill children.
Tilray will distribute its CBD 100 product to three hospitals in the state of Victoria via its wholly-owned subsidiary Tilray Australia New Zealand Pty Ltd. The products are being supplied to Royal Children’s Hospital, Monash Children’s Hospital and Austin Health with support from the Government of Victoria’s Department of Health and Human Services, Victoria (DHHS), where they will be distributed to children suffering from intractable epilepsy.
Tilray first announced that the company successfully exported medical cannabis products to Victoria in March 2017. The products were distributed to 29 critically ill children through a compassionate access scheme designed to fast-track medical cannabis access for pediatric patients in need. According to the government, these 29 patients became the first in Victoria to legally access medical cannabis.
Earlier this year, the Victorian government released an update on the status of the compassionate access scheme. According to the update, in less than one year the scheme “has already helped children see a reduction in seizures and has significantly improved their quality of life.” The additional number of patients gaining access over the next three years was labelled a “significant expansion” by the Victorian government.
Tilray CBD 100 is an oral solution of concentrated cannabinoid extract. Tilray CBD 100 has a target concentration of 100mg/ml CBD in a 25ml vial. The Tilray CBD 100 products, which will be supplied to Australian patients via compassionate access, were successfully exported from Nanaimo to Victoria, Australia, this month.
Tilray is proud to serve authorized medical cannabis patients in Australia and New Zealand. Prospective patients and interested physicians can contact Tilray at infoanz@tilray.com or 1800-361-664.
About Tilray
Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients in twelve countries spanning five continents.
This press release contains “forward-looking statements”, which may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Forward-looking statements involve significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.
